Name | Valproate semisodium |
Synonyms | Epival DIVALPROEX SODIUM divalproex sodium SODIUM DIVALPROATE SEMISODIUMVALPROATE Valproate semisodium Divalproex Sodium (200 mg) Dipropylacetic acid hemisodium salt Sodium 2-propylpentanoate 2-propylpentanoic acid |
CAS | 76584-70-8 |
EINECS | 202-303-5 |
InChI | InChI=1/2C8H16O2.Na/c2*1-3-5-7(6-4-2)8(9)10;/h2*7H,3-6H2,1-2H3,(H,9,10);/q;;+1/p-1 |
Molecular Formula | C8H17NaO2 |
Molar Mass | 168.21 |
Melting Point | 222 °C |
Boling Point | 220°C at 760 mmHg |
Flash Point | 116.6°C |
Solubility | Chloroform (Slightly), Methanol (Slightly) |
Vapor Presure | 0.0435mmHg at 25°C |
Appearance | Solid |
Color | White |
Storage Condition | Inert atmosphere,2-8°C |
In vitro study | Divalproex sodium enhances IM-induced cell growth inhibition, apoptosis, and cell cycle arrest in K562-S and K562-G cells. Divalproex sodium enhances the inhibitory effect of IM on SIRT1 expression in K562-S and K562-G cells. In K562-G cells, Divalproex sodium enhances the effect of IM on apoptosis, in part by inhibiting SIRT1. Divalproex (500 mg/kg) significantly enhanced the efflux of dopamine (DA) and acetylcholine (ACh) in rat hippocampus and only DA efflux in rat medial prefrontal cortex (mPFC), there was no effect on ACh, while a low dose of Divalproex,50 mg/kg, had no effect on DA or ACh in any area. Divalproex (50 mg/kg) combined with atypical APDs Olanzapine (1.0 mg/kg) or Aripiprazole (0.3 mg/kg) in HIP and mPFC these two antipsychotics (APDs) significantly enhanced the efflux effect on DA, but did not affect the efflux of ACh. |
HS Code | 2915900000 |
indication | 1. Acute treatment of manic or mixed episode disorder associated with bipolar disorder, with or without psychotic features; 2. Monotherapy and adjuvant therapy for complex partial seizures and simple and complex seizures; 3. Adjunctive therapy for multiple seizure types, including absence seizures; 4. Prevention of migraine. |
biological activity | Divalproex Sodium is a compound consisting of Sodium valproate and valproic acid in a 1:1 molar ratio in an enteric coating, is an HDAC inhibitor used in the treatment of epilepsy. |
Target | Value |